Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management.
Zhao EJ, Cheng CV, Mattman A, Chen LYC.
Lancet Haematol. 2021 May;8(5):e365-e375. doi: 10.1016/S2352-3026(21)00056-9.
Polyclonal hypergammaglobulinaemia: towards definition of a threshold.
Baillou C, Jacomet F, Dejoie T, Lureau P, Beuvon C, Grados A, Martins P, Roblot P, Puyade M, Martin M.
Postgrad Med J. 2023 May 22;99(1170):296-301. doi: 10.1136/postgradmedj-2021-140591.
Hypergammaglobulinaemia and autoimmune rheumatic diseases.
Ehrenstein MR, Isenberg DA.
Ann Rheum Dis. 1992 Nov;51(11):1185-7. doi: 10.1136/ard.51.11.1185.
Hyper-IgE syndromes.
Ring J, Landthaler M.
Curr Probl Dermatol. 1989;18:79-88. doi: 10.1159/000416841.
A novel gain-of-function missense variant in PLCG2 associated with autoinflammation and hypergammaglobulinaemia.
Itakura T, Sasaki H, Hosoya T, Yamaguchi T, Mimori E, Saimon Y, Iwai H, Umezawa N, Kawata D, Kimura N, Kurata M, Shimizu M, Yasuda S.
Rheumatology (Oxford). 2023 Nov 2;62(11):e319-e321. doi: 10.1093/rheumatology/kead193.
[Hypergammaglobulinaemia in cirrhosis (author's transl)].
Fischer D, Paraf A.
Gastroenterol Clin Biol. 1980 Jun-Jul;4(6-7):474-85.
Hyper-IgM syndromes.
Durandy A, Peron S, Fischer A.
Curr Opin Rheumatol. 2006 Jul;18(4):369-76. doi: 10.1097/01.bor.0000231905.12172.b5.
Polyclonal hypergammaglobulinaemia with hyperviscosity syndrome.
Amati F, Canellini G, Beris P.
Br J Haematol. 2002 Jan;116(1):2. doi: 10.1046/j.1365-2141.2002.03208.x.
[Polyclonal hypergammaglobulinemia].
Maseki N.
Ryoikibetsu Shokogun Shirizu. 1998;(22 Pt 3):534-6.
Electron-beam therapy in scleredema adultorum with associated monoclonal hypergammaglobulinaemia.
Angeli-Besson C, Koeppel MC, Jacquet P, Andrac L, Sayag J.
Br J Dermatol. 1994 Mar;130(3):394-7. doi: 10.1111/j.1365-2133.1994.tb02940.x.
